Dr. Anderson Chang brings over six years of drug development experience focused on antibody-drug conjugates (ADCs). At AbbVie, he led multiple preclinical ADC programs featuring novel targets, payloads, and antibody formats. Anderson has strong expertise in cancer biology, target validation, and biomarker strategy to support preclinical discovery, IND-enabling studies and early clinical development. He played a key role in the discovery and preclinical development of ABBV-319, a first-in-class CD19-targeting glucocorticoid receptor modulator ADC currently in Phase I clinical trials.

Anderson earned B.Sc. in Biochemistry from the University of British Columbia and Ph.D. in Medical Biophysics from the University of Toronto. His scientific work has been published in leading journals, including Cancer Discovery and Blood.